| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Uterine Cervical Neoplasms | 70 | 2026 | 92 | 14.540 |
Why?
|
| Breast Neoplasms | 26 | 2026 | 170 | 6.090 |
Why?
|
| Early Detection of Cancer | 21 | 2026 | 59 | 5.740 |
Why?
|
| Mass Screening | 23 | 2026 | 116 | 4.880 |
Why?
|
| Female | 134 | 2026 | 4060 | 3.960 |
Why?
|
| Humans | 143 | 2026 | 6794 | 3.260 |
Why?
|
| HIV Infections | 19 | 2026 | 432 | 3.200 |
Why?
|
| Zambia | 35 | 2026 | 38 | 3.190 |
Why?
|
| Papillomavirus Infections | 17 | 2026 | 27 | 3.090 |
Why?
|
| Adult | 61 | 2026 | 2113 | 2.630 |
Why?
|
| Middle Aged | 54 | 2026 | 2108 | 2.340 |
Why?
|
| Ovarian Neoplasms | 16 | 2005 | 35 | 1.740 |
Why?
|
| Neoplasms | 8 | 2023 | 92 | 1.720 |
Why?
|
| Cervical Intraepithelial Neoplasia | 9 | 2019 | 9 | 1.480 |
Why?
|
| Papillomaviridae | 16 | 2024 | 25 | 1.460 |
Why?
|
| Uterine Cervical Dysplasia | 3 | 2026 | 6 | 1.380 |
Why?
|
| Endometrial Neoplasms | 7 | 2024 | 25 | 1.330 |
Why?
|
| Prospective Studies | 19 | 2026 | 331 | 1.250 |
Why?
|
| Developing Countries | 10 | 2023 | 38 | 1.220 |
Why?
|
| Artificial Intelligence | 2 | 2026 | 31 | 1.140 |
Why?
|
| Health Services Accessibility | 10 | 2024 | 145 | 1.090 |
Why?
|
| Community Health Planning | 4 | 2018 | 5 | 1.060 |
Why?
|
| Smartphone | 2 | 2024 | 6 | 1.020 |
Why?
|
| Dendritic Cells | 10 | 2002 | 23 | 1.010 |
Why?
|
| Medical Oncology | 3 | 2024 | 10 | 1.000 |
Why?
|
| Adenocarcinoma | 11 | 2006 | 50 | 0.950 |
Why?
|
| Primary Health Care | 2 | 2024 | 78 | 0.950 |
Why?
|
| Vaginal Smears | 9 | 2011 | 11 | 0.940 |
Why?
|
| Cryotherapy | 6 | 2025 | 7 | 0.940 |
Why?
|
| Health Promotion | 4 | 2019 | 89 | 0.920 |
Why?
|
| African Americans | 9 | 2007 | 264 | 0.870 |
Why?
|
| Health Knowledge, Attitudes, Practice | 7 | 2018 | 153 | 0.850 |
Why?
|
| Africa South of the Sahara | 17 | 2026 | 23 | 0.840 |
Why?
|
| Ultrasonography, Mammary | 2 | 2020 | 2 | 0.840 |
Why?
|
| Virtual Reality | 2 | 2021 | 2 | 0.840 |
Why?
|
| Gynecology | 1 | 2024 | 19 | 0.820 |
Why?
|
| Aged | 24 | 2026 | 1539 | 0.760 |
Why?
|
| Algorithms | 2 | 2024 | 83 | 0.750 |
Why?
|
| Histocompatibility Antigens Class I | 9 | 2000 | 10 | 0.750 |
Why?
|
| Healthcare Disparities | 6 | 2024 | 83 | 0.740 |
Why?
|
| Neoplasm Staging | 15 | 2024 | 45 | 0.720 |
Why?
|
| Tretinoin | 6 | 1998 | 30 | 0.720 |
Why?
|
| United States | 13 | 2024 | 1019 | 0.680 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2020 | 6 | 0.670 |
Why?
|
| Delivery of Health Care | 7 | 2022 | 71 | 0.660 |
Why?
|
| Sensitivity and Specificity | 6 | 2026 | 98 | 0.650 |
Why?
|
| Papanicolaou Test | 6 | 2016 | 7 | 0.650 |
Why?
|
| Socioeconomic Factors | 9 | 2024 | 197 | 0.640 |
Why?
|
| Program Evaluation | 3 | 2015 | 46 | 0.630 |
Why?
|
| Community Participation | 5 | 2007 | 13 | 0.630 |
Why?
|
| Antineoplastic Agents | 7 | 2002 | 72 | 0.620 |
Why?
|
| Point-of-Care Systems | 2 | 2016 | 8 | 0.610 |
Why?
|
| Intercellular Adhesion Molecule-1 | 5 | 1999 | 9 | 0.600 |
Why?
|
| Program Development | 3 | 2015 | 34 | 0.590 |
Why?
|
| Antigens, Neoplasm | 4 | 2000 | 7 | 0.580 |
Why?
|
| Breast Diseases | 1 | 2018 | 3 | 0.560 |
Why?
|
| Rural Health Services | 1 | 2018 | 2 | 0.560 |
Why?
|
| Tumor Cells, Cultured | 19 | 2002 | 72 | 0.560 |
Why?
|
| Acquired Immunodeficiency Syndrome | 3 | 2013 | 65 | 0.550 |
Why?
|
| Genital Neoplasms, Female | 4 | 2025 | 9 | 0.530 |
Why?
|
| Young Adult | 10 | 2026 | 567 | 0.500 |
Why?
|
| Gene Expression Regulation, Neoplastic | 6 | 1998 | 88 | 0.500 |
Why?
|
| Poverty | 5 | 2022 | 64 | 0.500 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2016 | 4 | 0.500 |
Why?
|
| Immunotherapy, Adoptive | 3 | 2000 | 5 | 0.480 |
Why?
|
| Incidence | 7 | 2024 | 197 | 0.480 |
Why?
|
| T-Lymphocytes, Cytotoxic | 6 | 2002 | 7 | 0.470 |
Why?
|
| Telemedicine | 2 | 2020 | 43 | 0.470 |
Why?
|
| Histocompatibility Antigens Class II | 4 | 1999 | 5 | 0.460 |
Why?
|
| Health Status Disparities | 2 | 2024 | 83 | 0.450 |
Why?
|
| Electrosurgery | 3 | 2024 | 4 | 0.440 |
Why?
|
| Women's Health | 6 | 2016 | 24 | 0.440 |
Why?
|
| Referral and Consultation | 4 | 2024 | 61 | 0.430 |
Why?
|
| Colposcopy | 4 | 2015 | 4 | 0.420 |
Why?
|
| Condylomata Acuminata | 1 | 2013 | 1 | 0.420 |
Why?
|
| Anus Neoplasms | 1 | 2013 | 3 | 0.420 |
Why?
|
| Interleukin-10 | 3 | 2002 | 10 | 0.410 |
Why?
|
| Male | 10 | 2024 | 3671 | 0.390 |
Why?
|
| Community Health Workers | 3 | 2013 | 13 | 0.380 |
Why?
|
| Ascitic Fluid | 3 | 2001 | 6 | 0.380 |
Why?
|
| Prognosis | 8 | 2024 | 220 | 0.380 |
Why?
|
| Adolescent | 13 | 2025 | 869 | 0.380 |
Why?
|
| Rural Population | 6 | 2024 | 16 | 0.380 |
Why?
|
| Preventive Health Services | 2 | 2012 | 21 | 0.370 |
Why?
|
| Immunophenotyping | 8 | 2002 | 11 | 0.370 |
Why?
|
| Attitude to Health | 3 | 2012 | 46 | 0.360 |
Why?
|
| Treatment Outcome | 6 | 2025 | 500 | 0.360 |
Why?
|
| Immunotherapy | 3 | 2002 | 16 | 0.360 |
Why?
|
| T-Lymphocytes | 3 | 2000 | 20 | 0.350 |
Why?
|
| Cystadenocarcinoma, Papillary | 2 | 2002 | 2 | 0.350 |
Why?
|
| DNA-Binding Proteins | 6 | 2002 | 38 | 0.350 |
Why?
|
| Health Resources | 1 | 2011 | 12 | 0.350 |
Why?
|
| Carcinoma, Squamous Cell | 5 | 2006 | 17 | 0.340 |
Why?
|
| Cancer Survivors | 2 | 2021 | 9 | 0.340 |
Why?
|
| CD8-Positive T-Lymphocytes | 6 | 2002 | 23 | 0.340 |
Why?
|
| Uterine Neoplasms | 3 | 2002 | 29 | 0.330 |
Why?
|
| Interferon-gamma | 7 | 2001 | 23 | 0.330 |
Why?
|
| Vagina | 2 | 2025 | 14 | 0.320 |
Why?
|
| Computer Simulation | 2 | 2021 | 26 | 0.320 |
Why?
|
| Peer Group | 1 | 2010 | 34 | 0.320 |
Why?
|
| Patient Education as Topic | 1 | 2010 | 58 | 0.310 |
Why?
|
| Oncogene Proteins, Viral | 4 | 2002 | 7 | 0.310 |
Why?
|
| Health Care Coalitions | 2 | 2006 | 4 | 0.310 |
Why?
|
| Cohort Studies | 8 | 2023 | 285 | 0.300 |
Why?
|
| Endothelial Growth Factors | 2 | 1999 | 4 | 0.300 |
Why?
|
| Lymphokines | 2 | 1999 | 8 | 0.300 |
Why?
|
| Acetic Acid | 3 | 2019 | 4 | 0.300 |
Why?
|
| Transforming Growth Factor beta | 2 | 2001 | 55 | 0.300 |
Why?
|
| Antigens, Surface | 2 | 1999 | 4 | 0.290 |
Why?
|
| Quality of Life | 3 | 2026 | 184 | 0.290 |
Why?
|
| Tumor Virus Infections | 6 | 2002 | 10 | 0.290 |
Why?
|
| Survival Analysis | 6 | 2024 | 95 | 0.290 |
Why?
|
| Cervix Uteri | 3 | 2015 | 9 | 0.290 |
Why?
|
| Reproductive Health Services | 1 | 2008 | 2 | 0.290 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2008 | 15 | 0.280 |
Why?
|
| Cooperative Behavior | 3 | 2019 | 28 | 0.280 |
Why?
|
| Flow Cytometry | 8 | 2002 | 48 | 0.270 |
Why?
|
| Social Justice | 1 | 2007 | 7 | 0.270 |
Why?
|
| Community Health Services | 1 | 2007 | 35 | 0.260 |
Why?
|
| Lymphocyte Subsets | 3 | 2002 | 5 | 0.260 |
Why?
|
| Carcinoma | 4 | 1997 | 13 | 0.260 |
Why?
|
| Global Health | 5 | 2022 | 54 | 0.250 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 3 | 2001 | 4 | 0.250 |
Why?
|
| Predictive Value of Tests | 5 | 2016 | 127 | 0.250 |
Why?
|
| Healthy People Programs | 1 | 2006 | 2 | 0.250 |
Why?
|
| HIV Seropositivity | 2 | 2018 | 25 | 0.240 |
Why?
|
| Blood Transfusion | 2 | 2003 | 8 | 0.240 |
Why?
|
| Patient Satisfaction | 1 | 2026 | 31 | 0.240 |
Why?
|
| Income | 5 | 2022 | 30 | 0.240 |
Why?
|
| Reproduction | 1 | 2005 | 4 | 0.230 |
Why?
|
| Diathermy | 1 | 2025 | 1 | 0.230 |
Why?
|
| Clinical Competence | 2 | 2021 | 51 | 0.230 |
Why?
|
| Microbiota | 1 | 2025 | 8 | 0.230 |
Why?
|
| Patient Care Team | 1 | 2025 | 13 | 0.230 |
Why?
|
| Patient Navigation | 1 | 2025 | 7 | 0.230 |
Why?
|
| Dairy Products | 1 | 2005 | 1 | 0.230 |
Why?
|
| Obesity | 1 | 2007 | 226 | 0.220 |
Why?
|
| Prevalence | 5 | 2015 | 259 | 0.220 |
Why?
|
| Cytotoxicity, Immunologic | 3 | 2000 | 18 | 0.220 |
Why?
|
| Lung Neoplasms | 2 | 2002 | 45 | 0.220 |
Why?
|
| Ablation Techniques | 1 | 2024 | 1 | 0.220 |
Why?
|
| Demography | 2 | 2015 | 26 | 0.220 |
Why?
|
| ROC Curve | 1 | 2024 | 28 | 0.210 |
Why?
|
| Prostatic Neoplasms | 1 | 2005 | 45 | 0.210 |
Why?
|
| Lymphocytes | 2 | 2001 | 17 | 0.210 |
Why?
|
| Life Expectancy | 1 | 2024 | 10 | 0.210 |
Why?
|
| History, 20th Century | 1 | 2024 | 13 | 0.210 |
Why?
|
| CD8 Antigens | 2 | 2000 | 3 | 0.210 |
Why?
|
| Diet | 1 | 2005 | 111 | 0.210 |
Why?
|
| Photography | 2 | 2015 | 26 | 0.200 |
Why?
|
| Specimen Handling | 1 | 2003 | 6 | 0.200 |
Why?
|
| Retrospective Studies | 3 | 2019 | 681 | 0.190 |
Why?
|
| Radiotherapy | 1 | 2002 | 4 | 0.190 |
Why?
|
| Biomedical Research | 1 | 2022 | 34 | 0.190 |
Why?
|
| Cystadenocarcinoma, Serous | 1 | 2002 | 2 | 0.190 |
Why?
|
| Receptor, ErbB-2 | 1 | 2002 | 16 | 0.190 |
Why?
|
| Cisplatin | 2 | 2005 | 9 | 0.180 |
Why?
|
| Dependovirus | 5 | 2000 | 8 | 0.180 |
Why?
|
| Cross-Sectional Studies | 4 | 2016 | 506 | 0.180 |
Why?
|
| Membrane Glycoproteins | 6 | 2002 | 65 | 0.180 |
Why?
|
| Shoulder | 1 | 2021 | 6 | 0.180 |
Why?
|
| Liver Neoplasms | 2 | 2000 | 63 | 0.180 |
Why?
|
| Arm | 1 | 2021 | 7 | 0.180 |
Why?
|
| Cell Differentiation | 4 | 2000 | 101 | 0.180 |
Why?
|
| Survival Rate | 6 | 2020 | 111 | 0.180 |
Why?
|
| Neoplasm Proteins | 1 | 2001 | 18 | 0.170 |
Why?
|
| Age Factors | 3 | 2025 | 193 | 0.170 |
Why?
|
| Heat-Shock Proteins | 2 | 1998 | 9 | 0.170 |
Why?
|
| Child, Orphaned | 1 | 2021 | 1 | 0.170 |
Why?
|
| Learning | 1 | 2021 | 11 | 0.170 |
Why?
|
| CD56 Antigen | 4 | 2002 | 4 | 0.170 |
Why?
|
| Democratic Republic of the Congo | 1 | 2020 | 1 | 0.170 |
Why?
|
| Biopsy, Large-Core Needle | 1 | 2020 | 1 | 0.170 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2020 | 5 | 0.170 |
Why?
|
| Image-Guided Biopsy | 1 | 2020 | 3 | 0.170 |
Why?
|
| Breast | 1 | 2020 | 9 | 0.170 |
Why?
|
| Africa | 4 | 2022 | 12 | 0.170 |
Why?
|
| Feasibility Studies | 1 | 2020 | 44 | 0.170 |
Why?
|
| Lost to Follow-Up | 1 | 2020 | 3 | 0.170 |
Why?
|
| Lymphatic Metastasis | 2 | 1998 | 8 | 0.170 |
Why?
|
| Cell Transformation, Viral | 3 | 1999 | 4 | 0.170 |
Why?
|
| Ultrasonography, Interventional | 1 | 2020 | 17 | 0.170 |
Why?
|
| Diagnosis, Differential | 1 | 2020 | 79 | 0.170 |
Why?
|
| Risk Assessment | 2 | 2015 | 197 | 0.160 |
Why?
|
| Dendrites | 1 | 2000 | 2 | 0.160 |
Why?
|
| Hyperthermia, Induced | 1 | 2019 | 2 | 0.160 |
Why?
|
| Interleukin-2 | 5 | 2002 | 12 | 0.150 |
Why?
|
| Simulation Training | 1 | 2019 | 4 | 0.150 |
Why?
|
| Gynecologic Surgical Procedures | 1 | 2019 | 10 | 0.150 |
Why?
|
| Pregnancy | 5 | 2023 | 599 | 0.150 |
Why?
|
| Risk Factors | 5 | 2021 | 767 | 0.150 |
Why?
|
| Genes, Viral | 1 | 1998 | 1 | 0.150 |
Why?
|
| Oncogenes | 1 | 1998 | 4 | 0.150 |
Why?
|
| Macrophages | 1 | 1999 | 40 | 0.150 |
Why?
|
| HIV Seronegativity | 1 | 2018 | 4 | 0.150 |
Why?
|
| Child | 4 | 2022 | 524 | 0.140 |
Why?
|
| Residence Characteristics | 1 | 2018 | 36 | 0.140 |
Why?
|
| Proportional Hazards Models | 4 | 2025 | 169 | 0.140 |
Why?
|
| Interleukin-4 | 5 | 2001 | 9 | 0.140 |
Why?
|
| Human papillomavirus 16 | 2 | 2015 | 2 | 0.140 |
Why?
|
| Lymph Node Excision | 2 | 1998 | 7 | 0.140 |
Why?
|
| Transcription, Genetic | 1 | 1998 | 40 | 0.140 |
Why?
|
| Cell Division | 5 | 2002 | 40 | 0.140 |
Why?
|
| Health Services Needs and Demand | 2 | 2015 | 32 | 0.140 |
Why?
|
| Cytokines | 4 | 2002 | 80 | 0.140 |
Why?
|
| Immunologic Factors | 1 | 1998 | 7 | 0.140 |
Why?
|
| Killer Cells, Natural | 3 | 2002 | 35 | 0.130 |
Why?
|
| Follow-Up Studies | 4 | 2025 | 268 | 0.130 |
Why?
|
| Papillomavirus Vaccines | 2 | 2015 | 8 | 0.130 |
Why?
|
| Isotretinoin | 1 | 1997 | 4 | 0.130 |
Why?
|
| Logistic Models | 2 | 2017 | 165 | 0.130 |
Why?
|
| Combined Modality Therapy | 5 | 2006 | 33 | 0.130 |
Why?
|
| CD4 Lymphocyte Count | 2 | 2007 | 45 | 0.130 |
Why?
|
| Alabama | 3 | 2006 | 9 | 0.130 |
Why?
|
| Adenosine Triphosphatases | 1 | 2016 | 6 | 0.120 |
Why?
|
| Cell Cycle Proteins | 1 | 2016 | 22 | 0.120 |
Why?
|
| Ovary | 2 | 1997 | 19 | 0.120 |
Why?
|
| Uterine Cervical Diseases | 1 | 2015 | 1 | 0.120 |
Why?
|
| Histocytochemistry | 1 | 2015 | 5 | 0.120 |
Why?
|
| Staining and Labeling | 1 | 2015 | 10 | 0.120 |
Why?
|
| Observer Variation | 1 | 2015 | 11 | 0.120 |
Why?
|
| Mississippi | 2 | 2007 | 5 | 0.120 |
Why?
|
| Cost-Benefit Analysis | 3 | 2025 | 48 | 0.120 |
Why?
|
| Teratoma | 1 | 1995 | 1 | 0.110 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2015 | 3 | 0.110 |
Why?
|
| Human papillomavirus 18 | 1 | 2015 | 1 | 0.110 |
Why?
|
| Perforin | 4 | 2002 | 5 | 0.110 |
Why?
|
| Pore Forming Cytotoxic Proteins | 4 | 2002 | 6 | 0.110 |
Why?
|
| RNA, Messenger | 7 | 2000 | 190 | 0.110 |
Why?
|
| Minority Groups | 2 | 2007 | 63 | 0.110 |
Why?
|
| Cytological Techniques | 1 | 2014 | 2 | 0.110 |
Why?
|
| Optical Imaging | 1 | 2014 | 2 | 0.110 |
Why?
|
| Social Class | 2 | 2016 | 46 | 0.110 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2015 | 72 | 0.110 |
Why?
|
| Blotting, Northern | 3 | 1998 | 25 | 0.110 |
Why?
|
| Topography, Medical | 1 | 2013 | 1 | 0.100 |
Why?
|
| Alphapapillomavirus | 1 | 2013 | 1 | 0.100 |
Why?
|
| Cell Transformation, Neoplastic | 3 | 1999 | 19 | 0.100 |
Why?
|
| Sex Education | 1 | 2013 | 3 | 0.100 |
Why?
|
| HIV | 1 | 2013 | 16 | 0.100 |
Why?
|
| Culturally Competent Care | 1 | 2013 | 8 | 0.100 |
Why?
|
| Probability | 1 | 2013 | 20 | 0.100 |
Why?
|
| Receptors, Interleukin-2 | 3 | 2002 | 5 | 0.100 |
Why?
|
| Urban Population | 3 | 2024 | 85 | 0.100 |
Why?
|
| Immunohistochemistry | 5 | 2016 | 118 | 0.100 |
Why?
|
| Aged, 80 and over | 5 | 2003 | 497 | 0.100 |
Why?
|
| Multivariate Analysis | 1 | 2013 | 104 | 0.100 |
Why?
|
| Time Factors | 4 | 2002 | 321 | 0.100 |
Why?
|
| Odds Ratio | 2 | 2017 | 82 | 0.100 |
Why?
|
| Fertility | 2 | 2023 | 8 | 0.100 |
Why?
|
| CD4-Positive T-Lymphocytes | 3 | 2002 | 38 | 0.100 |
Why?
|
| Genital Diseases, Female | 1 | 2012 | 3 | 0.090 |
Why?
|
| Metagenome | 1 | 2012 | 4 | 0.090 |
Why?
|
| Patient Preference | 1 | 2012 | 11 | 0.090 |
Why?
|
| Focus Groups | 2 | 2012 | 46 | 0.090 |
Why?
|
| Disease-Free Survival | 3 | 2006 | 24 | 0.090 |
Why?
|
| Social Stigma | 1 | 2012 | 58 | 0.090 |
Why?
|
| Patient Participation | 1 | 2012 | 32 | 0.090 |
Why?
|
| Health Plan Implementation | 1 | 2011 | 3 | 0.090 |
Why?
|
| Medical Informatics | 1 | 2011 | 8 | 0.090 |
Why?
|
| Mutation | 4 | 1999 | 97 | 0.080 |
Why?
|
| Viral Proteins | 3 | 1999 | 4 | 0.080 |
Why?
|
| Education | 1 | 2010 | 11 | 0.080 |
Why?
|
| Nurses | 1 | 2010 | 8 | 0.080 |
Why?
|
| Data Collection | 1 | 2010 | 38 | 0.080 |
Why?
|
| Blotting, Western | 4 | 2016 | 110 | 0.080 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 2 | 2000 | 5 | 0.080 |
Why?
|
| Lymph Nodes | 2 | 2001 | 9 | 0.080 |
Why?
|
| Leukocytes, Mononuclear | 2 | 2000 | 12 | 0.080 |
Why?
|
| Community-Institutional Relations | 2 | 2006 | 21 | 0.080 |
Why?
|
| Vascular Endothelial Growth Factors | 2 | 1999 | 4 | 0.080 |
Why?
|
| Vascular Endothelial Growth Factor A | 2 | 1999 | 30 | 0.070 |
Why?
|
| Gamma Rays | 2 | 1998 | 8 | 0.070 |
Why?
|
| Biopsy | 1 | 2008 | 36 | 0.070 |
Why?
|
| Reproducibility of Results | 2 | 2019 | 112 | 0.070 |
Why?
|
| Beneficence | 1 | 2007 | 1 | 0.070 |
Why?
|
| Personal Autonomy | 1 | 2007 | 6 | 0.070 |
Why?
|
| Culture | 1 | 2007 | 15 | 0.070 |
Why?
|
| Social Environment | 1 | 2007 | 17 | 0.070 |
Why?
|
| Sequence Analysis, DNA | 2 | 2025 | 18 | 0.070 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2000 | 57 | 0.070 |
Why?
|
| Feeding Behavior | 1 | 2007 | 38 | 0.070 |
Why?
|
| Confidence Intervals | 1 | 2007 | 17 | 0.070 |
Why?
|
| Smoking | 2 | 2006 | 86 | 0.070 |
Why?
|
| Public Health | 1 | 2007 | 40 | 0.070 |
Why?
|
| Pregnancy Complications, Neoplastic | 1 | 1987 | 3 | 0.060 |
Why?
|
| Parathyroid Neoplasms | 1 | 1987 | 4 | 0.060 |
Why?
|
| Hyperparathyroidism | 1 | 1987 | 7 | 0.060 |
Why?
|
| Exercise | 1 | 2007 | 55 | 0.060 |
Why?
|
| Cells, Cultured | 4 | 2000 | 234 | 0.060 |
Why?
|
| Social Change | 1 | 2006 | 3 | 0.060 |
Why?
|
| State Government | 1 | 2006 | 2 | 0.060 |
Why?
|
| Biomarkers, Tumor | 2 | 2016 | 51 | 0.060 |
Why?
|
| Research Support as Topic | 1 | 2006 | 20 | 0.060 |
Why?
|
| Medically Underserved Area | 1 | 2006 | 41 | 0.060 |
Why?
|
| Maternal Mortality | 1 | 2005 | 5 | 0.060 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2005 | 21 | 0.060 |
Why?
|
| Prenatal Care | 1 | 2005 | 13 | 0.060 |
Why?
|
| Interviews as Topic | 2 | 2018 | 77 | 0.060 |
Why?
|
| Longitudinal Studies | 1 | 2026 | 140 | 0.060 |
Why?
|
| DNA, Ribosomal | 1 | 2025 | 1 | 0.060 |
Why?
|
| DNA, Bacterial | 1 | 2025 | 2 | 0.060 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2025 | 7 | 0.060 |
Why?
|
| South Africa | 2 | 2022 | 68 | 0.060 |
Why?
|
| Qualitative Research | 2 | 2018 | 82 | 0.060 |
Why?
|
| Lactobacillus | 1 | 2025 | 6 | 0.060 |
Why?
|
| Infertility, Female | 1 | 2005 | 18 | 0.060 |
Why?
|
| Health Status | 1 | 2026 | 83 | 0.060 |
Why?
|
| Pregnancy Outcome | 1 | 2005 | 42 | 0.060 |
Why?
|
| Anti-HIV Agents | 1 | 2006 | 102 | 0.060 |
Why?
|
| DNA, Viral | 2 | 2015 | 10 | 0.060 |
Why?
|
| Pregnancy Complications | 1 | 2005 | 44 | 0.060 |
Why?
|
| Cell Line | 3 | 2001 | 124 | 0.050 |
Why?
|
| CD4-CD8 Ratio | 2 | 2001 | 5 | 0.050 |
Why?
|
| Mammography | 2 | 2019 | 8 | 0.050 |
Why?
|
| Parity | 2 | 2023 | 7 | 0.050 |
Why?
|
| Lymphocyte Activation | 2 | 2000 | 25 | 0.050 |
Why?
|
| Capacity Building | 1 | 2023 | 5 | 0.050 |
Why?
|
| Th1 Cells | 2 | 2001 | 3 | 0.050 |
Why?
|
| K562 Cells | 2 | 2000 | 3 | 0.050 |
Why?
|
| Quality of Health Care | 1 | 2023 | 27 | 0.050 |
Why?
|
| Reproductive History | 1 | 2023 | 1 | 0.050 |
Why?
|
| Sociology, Medical | 1 | 2003 | 1 | 0.050 |
Why?
|
| Receptors, IgG | 1 | 2002 | 1 | 0.050 |
Why?
|
| CD3 Complex | 1 | 2002 | 2 | 0.050 |
Why?
|
| Antigens, CD19 | 1 | 2002 | 2 | 0.050 |
Why?
|
| B-Lymphocytes | 1 | 2002 | 9 | 0.050 |
Why?
|
| Health Services Research | 1 | 2003 | 27 | 0.050 |
Why?
|
| Immunoglobulins | 2 | 2000 | 5 | 0.050 |
Why?
|
| Bibliometrics | 1 | 2022 | 8 | 0.050 |
Why?
|
| Antigens, CD | 2 | 2000 | 21 | 0.050 |
Why?
|
| Promoter Regions, Genetic | 2 | 1999 | 45 | 0.050 |
Why?
|
| Surveys and Questionnaires | 2 | 2018 | 280 | 0.050 |
Why?
|
| Mortality | 1 | 2022 | 43 | 0.050 |
Why?
|
| Fatal Outcome | 1 | 2002 | 13 | 0.050 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2002 | 3 | 0.050 |
Why?
|
| Trastuzumab | 1 | 2002 | 6 | 0.050 |
Why?
|
| Rituximab | 1 | 2002 | 3 | 0.050 |
Why?
|
| Cause of Death | 1 | 2022 | 82 | 0.050 |
Why?
|
| Research | 1 | 2022 | 26 | 0.050 |
Why?
|
| Bovine papillomavirus 1 | 2 | 1999 | 2 | 0.050 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2002 | 26 | 0.050 |
Why?
|
| Antibodies, Monoclonal | 1 | 2002 | 31 | 0.050 |
Why?
|
| Carcinoma, Papillary | 1 | 2002 | 3 | 0.050 |
Why?
|
| Cancer Care Facilities | 1 | 2021 | 3 | 0.040 |
Why?
|
| Self Report | 1 | 2021 | 35 | 0.040 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2001 | 35 | 0.040 |
Why?
|
| HLA-DR Antigens | 1 | 2001 | 6 | 0.040 |
Why?
|
| HLA-A2 Antigen | 1 | 2001 | 2 | 0.040 |
Why?
|
| Case-Control Studies | 1 | 2001 | 108 | 0.040 |
Why?
|
| Lymphocyte Count | 1 | 2001 | 6 | 0.040 |
Why?
|
| Family | 1 | 2021 | 27 | 0.040 |
Why?
|
| Immunity, Cellular | 1 | 2000 | 5 | 0.040 |
Why?
|
| Recombinant Fusion Proteins | 2 | 1997 | 10 | 0.040 |
Why?
|
| Cell Line, Transformed | 1 | 2000 | 9 | 0.040 |
Why?
|
| Delayed Diagnosis | 1 | 2020 | 5 | 0.040 |
Why?
|
| Regression Analysis | 1 | 2020 | 66 | 0.040 |
Why?
|
| Carrier Proteins | 2 | 1997 | 28 | 0.040 |
Why?
|
| Child, Preschool | 1 | 2021 | 258 | 0.040 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 2000 | 4 | 0.040 |
Why?
|
| Hepatic Artery | 1 | 2000 | 2 | 0.040 |
Why?
|
| Uric Acid | 1 | 2000 | 4 | 0.040 |
Why?
|
| Genetic Vectors | 1 | 2000 | 19 | 0.040 |
Why?
|
| Repressor Proteins | 1 | 1999 | 13 | 0.040 |
Why?
|
| Pilot Projects | 1 | 2019 | 89 | 0.040 |
Why?
|
| CD58 Antigens | 1 | 1999 | 1 | 0.040 |
Why?
|
| Antigens, CD1 | 1 | 1999 | 3 | 0.040 |
Why?
|
| CD40 Antigens | 1 | 1999 | 2 | 0.040 |
Why?
|
| B7-1 Antigen | 1 | 1999 | 3 | 0.040 |
Why?
|
| B7-2 Antigen | 1 | 1999 | 3 | 0.040 |
Why?
|
| Lipopolysaccharide Receptors | 1 | 1999 | 2 | 0.040 |
Why?
|
| Cell Adhesion | 1 | 1999 | 19 | 0.040 |
Why?
|
| Monocytes | 1 | 1999 | 14 | 0.040 |
Why?
|
| Cyclin D1 | 1 | 1999 | 4 | 0.040 |
Why?
|
| Genes, p53 | 1 | 1999 | 4 | 0.040 |
Why?
|
| Health Education | 2 | 2012 | 55 | 0.040 |
Why?
|
| Chemoprevention | 1 | 2019 | 9 | 0.040 |
Why?
|
| Databases as Topic | 1 | 1998 | 9 | 0.040 |
Why?
|
| Gene Expression | 1 | 1999 | 77 | 0.040 |
Why?
|
| Electronic Health Records | 1 | 2019 | 34 | 0.040 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 1 | 1998 | 8 | 0.040 |
Why?
|
| Viral Interference | 1 | 1998 | 1 | 0.040 |
Why?
|
| Social Determinants of Health | 1 | 2018 | 22 | 0.040 |
Why?
|
| Radiation Dosage | 1 | 1998 | 8 | 0.040 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 1998 | 4 | 0.040 |
Why?
|
| Cytoskeleton | 1 | 1998 | 4 | 0.030 |
Why?
|
| Ultrasonography | 2 | 1995 | 38 | 0.030 |
Why?
|
| Population Groups | 1 | 2017 | 5 | 0.030 |
Why?
|
| Isoenzymes | 1 | 1998 | 15 | 0.030 |
Why?
|
| Immune System | 1 | 1998 | 14 | 0.030 |
Why?
|
| Protein Kinase C | 1 | 1998 | 31 | 0.030 |
Why?
|
| Keratinocytes | 1 | 1997 | 9 | 0.030 |
Why?
|
| Transferases | 1 | 1997 | 1 | 0.030 |
Why?
|
| Genes, ras | 1 | 1997 | 2 | 0.030 |
Why?
|
| Alkyl and Aryl Transferases | 1 | 1997 | 3 | 0.030 |
Why?
|
| Serine Endopeptidases | 1 | 1997 | 10 | 0.030 |
Why?
|
| Proteins | 1 | 1997 | 41 | 0.030 |
Why?
|
| Cell Aggregation | 1 | 1997 | 3 | 0.030 |
Why?
|
| Mucins | 1 | 1997 | 5 | 0.030 |
Why?
|
| Cytoplasm | 1 | 1997 | 7 | 0.030 |
Why?
|
| Polymerase Chain Reaction | 4 | 1999 | 43 | 0.030 |
Why?
|
| Up-Regulation | 1 | 1997 | 94 | 0.030 |
Why?
|
| Actins | 1 | 1997 | 28 | 0.030 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 1997 | 34 | 0.030 |
Why?
|
| Cell Phone | 1 | 2016 | 6 | 0.030 |
Why?
|
| Clinical Protocols | 1 | 2016 | 13 | 0.030 |
Why?
|
| Colorimetry | 1 | 2016 | 1 | 0.030 |
Why?
|
| Valosin Containing Protein | 1 | 2016 | 2 | 0.030 |
Why?
|
| Electrophoresis, Gel, Two-Dimensional | 1 | 2016 | 4 | 0.030 |
Why?
|
| Cameroon | 1 | 2015 | 2 | 0.030 |
Why?
|
| Models, Theoretical | 1 | 2015 | 15 | 0.030 |
Why?
|
| Vulvar Neoplasms | 1 | 1995 | 2 | 0.030 |
Why?
|
| CA-125 Antigen | 1 | 1995 | 2 | 0.030 |
Why?
|
| Genotyping Techniques | 1 | 2015 | 2 | 0.030 |
Why?
|
| Marriage | 1 | 2013 | 7 | 0.030 |
Why?
|
| Counseling | 1 | 2013 | 29 | 0.030 |
Why?
|
| Vaccination | 1 | 2013 | 49 | 0.030 |
Why?
|
| Vaginosis, Bacterial | 1 | 2012 | 2 | 0.020 |
Why?
|
| Bacteria | 1 | 2012 | 9 | 0.020 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2003 | 23 | 0.020 |
Why?
|
| Government Programs | 1 | 2012 | 5 | 0.020 |
Why?
|
| Probiotics | 1 | 2012 | 10 | 0.020 |
Why?
|
| Preventive Medicine | 1 | 2011 | 5 | 0.020 |
Why?
|
| Motivation | 1 | 2012 | 42 | 0.020 |
Why?
|
| Risk | 1 | 2011 | 43 | 0.020 |
Why?
|
| Social Support | 1 | 2012 | 67 | 0.020 |
Why?
|
| Histocompatibility Testing | 2 | 2002 | 4 | 0.020 |
Why?
|
| Papillomavirus E7 Proteins | 2 | 2001 | 4 | 0.020 |
Why?
|
| Phenotype | 2 | 2001 | 91 | 0.020 |
Why?
|
| Chromatography, Affinity | 2 | 1999 | 3 | 0.020 |
Why?
|
| Molecular Sequence Data | 2 | 1999 | 70 | 0.020 |
Why?
|
| Base Sequence | 2 | 1999 | 65 | 0.020 |
Why?
|
| Carcinoma, Adenosquamous | 1 | 2006 | 1 | 0.020 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2006 | 5 | 0.020 |
Why?
|
| Neoplasm Metastasis | 1 | 2006 | 22 | 0.020 |
Why?
|
| Cotinine | 1 | 2006 | 21 | 0.020 |
Why?
|
| Health Priorities | 1 | 2006 | 6 | 0.010 |
Why?
|
| Fluorouracil | 1 | 2005 | 3 | 0.010 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2005 | 4 | 0.010 |
Why?
|
| Infusions, Intravenous | 1 | 2005 | 22 | 0.010 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2005 | 13 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 2005 | 50 | 0.010 |
Why?
|
| Ureteral Diseases | 1 | 1984 | 1 | 0.010 |
Why?
|
| Ureteral Obstruction | 1 | 1984 | 1 | 0.010 |
Why?
|
| Urinary Fistula | 1 | 1984 | 2 | 0.010 |
Why?
|
| Vaginal Fistula | 1 | 1984 | 2 | 0.010 |
Why?
|
| Hysterectomy | 1 | 1984 | 12 | 0.010 |
Why?
|
| Urinary Bladder | 1 | 1983 | 13 | 0.010 |
Why?
|
| Labor, Obstetric | 1 | 1983 | 14 | 0.010 |
Why?
|
| Hematocrit | 1 | 2003 | 12 | 0.010 |
Why?
|
| Transplantation, Homologous | 1 | 2003 | 16 | 0.010 |
Why?
|
| Hemoglobins | 1 | 2003 | 30 | 0.010 |
Why?
|
| Th2 Cells | 1 | 2001 | 4 | 0.010 |
Why?
|
| Virus Integration | 1 | 2000 | 1 | 0.010 |
Why?
|
| Antigen Presentation | 1 | 2000 | 3 | 0.010 |
Why?
|
| Transfection | 1 | 2000 | 56 | 0.010 |
Why?
|
| Colony-Forming Units Assay | 1 | 1999 | 3 | 0.010 |
Why?
|
| Repetitive Sequences, Nucleic Acid | 1 | 1999 | 5 | 0.010 |
Why?
|
| Gene Expression Regulation, Viral | 1 | 1999 | 4 | 0.010 |
Why?
|
| Protein Binding | 1 | 1999 | 29 | 0.010 |
Why?
|
| HLA-C Antigens | 1 | 1999 | 1 | 0.010 |
Why?
|
| HLA-B Antigens | 1 | 1999 | 2 | 0.010 |
Why?
|
| Intracellular Fluid | 1 | 1999 | 3 | 0.010 |
Why?
|
| HLA-A Antigens | 1 | 1999 | 5 | 0.010 |
Why?
|
| Adenoma | 1 | 1999 | 7 | 0.010 |
Why?
|
| Virus Replication | 1 | 1998 | 7 | 0.010 |
Why?
|
| Protein Kinase C-alpha | 1 | 1998 | 2 | 0.010 |
Why?
|
| Carbazoles | 1 | 1998 | 4 | 0.010 |
Why?
|
| Maleimides | 1 | 1998 | 5 | 0.010 |
Why?
|
| Staurosporine | 1 | 1998 | 4 | 0.010 |
Why?
|
| Indoles | 1 | 1998 | 11 | 0.010 |
Why?
|
| Enzyme Inhibitors | 1 | 1998 | 53 | 0.010 |
Why?
|
| Immunosorbent Techniques | 1 | 1997 | 1 | 0.010 |
Why?
|
| Peptide Mapping | 1 | 1997 | 1 | 0.010 |
Why?
|
| Sulfur Radioisotopes | 1 | 1997 | 1 | 0.010 |
Why?
|
| Maltose-Binding Proteins | 1 | 1997 | 1 | 0.010 |
Why?
|
| Molecular Weight | 1 | 1997 | 7 | 0.010 |
Why?
|
| HeLa Cells | 1 | 1997 | 15 | 0.010 |
Why?
|
| Binding Sites | 1 | 1997 | 24 | 0.010 |
Why?
|
| Peptide Fragments | 1 | 1997 | 23 | 0.010 |
Why?
|
| DNA | 1 | 1997 | 39 | 0.010 |
Why?
|
| Farnesyltranstransferase | 1 | 1997 | 2 | 0.010 |
Why?
|
| DNA Mutational Analysis | 1 | 1997 | 15 | 0.010 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 1997 | 2 | 0.010 |
Why?
|
| Genetic Markers | 1 | 1997 | 7 | 0.010 |
Why?
|
| Genes, Tumor Suppressor | 1 | 1997 | 8 | 0.010 |
Why?
|
| Epithelium | 1 | 1997 | 22 | 0.010 |
Why?
|
| DNA Primers | 1 | 1997 | 23 | 0.010 |
Why?
|
| Mice | 1 | 1998 | 746 | 0.010 |
Why?
|
| Animals | 1 | 1998 | 1875 | 0.010 |
Why?
|
| Neoplasm Invasiveness | 1 | 1984 | 13 | 0.000 |
Why?
|
| Urinary Catheterization | 1 | 1983 | 3 | 0.000 |
Why?
|
| Uterine Contraction | 1 | 1983 | 3 | 0.000 |
Why?
|